PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Alzheimer Dis Assoc Disord. Author manuscript; available in PMC Jan 1, 2010.
Published in final edited form as:
PMCID: PMC2743905
NIHMSID: NIHMS84738
A New Scale Measuring Psychological Impact of Genetic Susceptibility Testing for Alzheimer’s Disease
Winston W. Chung, B.A.,1 Clara A. Chen, M.H.S.,5 L.Adrienne Cupples, Ph.D.,3,4 J. Scott Roberts, Ph.D.,6 Susan C. Hiraki, M.S.,1 Anil K. Nair, M.D.,1 Robert C. Green, M.D., M.P.H.,1,2,4 and Robert A. Stern, Ph.D.1
1Dept. of Neurology, Boston University School of Medicine
2Dept. of Medicine (Genetics Program), Boston University School of Medicine
3Dept. of Biostatistics, Boston University School of Public Health
4Dept. of Epidemiology, Boston University School of Public Health
5Data Coordinating Center, Boston University School of Public Health
6Department of Health Behavior & Health Education, University of Michigan School of Public Health
Corresponding Author: Robert A. Stern, PhD Associate Professor of Neurology Boston University School of Medicine 715 Albany Street, R-7800, Boston, MA 02118 Tel: (617) 638-5678; Fax: (617) 414-1197 E-mail: bobstern/at/bu.edu
This paper describes the development and psychometric properties of a new scale for assessing the psychological impact of genetic susceptibility testing for Alzheimer’s disease (AD). The new instrument, The REVEAL Impact of Genetic Testing for Alzheimer’s disease (IGT-AD) was designed to examine the unique nature of genetic information and the disease course of AD. The scale was tested as a part of a multicenter clinical trial designed to evaluate the impact of AD risk assessment and data was collected from 276 participants in the study. Using an iterative process of Principal Component Analysis and Cronbach’s alpha, the final 16 item IGT-AD was found to have a two factor structure with excellent internal reliability. Construct validity was established by patterns of correlation with other standardized self-reported measures. This scale should be useful in the identification of patients who maybe susceptible to the negative effects of receiving genetic information, monitoring of patients who have received genetic information, and as a tool for researchers who wish to study the effects of genetic susceptibility testing for AD.
Keywords: Alzheimer’s disease genetics, genetic testing, Alzheimer’s disease risk assessment
Alzheimer’s disease (AD) is the most common cause of all the dementing disorders 1. With the oldest population groups rapidly growing in the United States, the number of AD patients is expected to triple in the U.S. between 2000 and 2050, from 4.5 million to 13.2 million people with AD 2. The increase in the number of AD patients is a matter of great concern not only from an individual’s perspective, but also from an economic and pubic health point of view 3.
Mutations in three genes, amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2), have been linked to rare early-onset forms of AD, with symptoms that usually begin in the 4th or 5th decades. Polymorphisms in a number of other genes, in particular apolipoprotein E (APOE) and neuronal sortilin-related receptor (SORL1), are associated with the more common late-onset form of AD 4, 5. APOE and SORL1 are susceptibility genes that are neither necessary nor sufficient to cause AD. This limitation, coupled with a general lack of treatment options for AD, has prompted several consensus statements to caution against the introduction of clinical susceptibility testing of genes in asymptomatic individuals 6-9. At the same time, the lack of scientific data also prompted these statements to encourage research on the benefits and limitations of disclosing genetic susceptibility information. With the growing number of individuals with AD and the even greater number of older Americans at risk for AD, it is likely that genetic susceptibility testing will become an important clinical, ethical, and research issue in the near future.
The REVEAL Study (Risk Evaluation and Education for Alzheimer’s Disease) is a series of randomized clinical trials designed to evaluate the impact of risk assessment, including APOE genotype disclosure, for AD. The study protocol was developed by a multidisciplinary team of experts in the fields of AD, neurology, genetics, genetic counseling, psychology, and bioethics, many of whom had previously been involved in the consensus statements against APOE genetic susceptibility testing. A primary aim of the REVEAL study was to determine whether AD genetic risk assessment can be provided safely and effectively to adult children and siblings of AD patients. Thus far, study results based on established outcome measures such as the Center for Epidemiologic Studies Depression Scale (CES-D), Beck Anxiety Inventory (BAI), and Impact of Event Scale (IES) have revealed that, in general, AD genetic risk assessment can be disclosed safely 10-12.
In a separate but related study that collected qualitative data from select REVEAL participants approximately eighteen months after their risk assessment disclosure, there was some anecdotal evidence to suggest that some participants did experience a certain amount of emotional distress 13. A few participants described their genetic results as “depressing,” “frightening,” and “disappointing.” This pattern of results has previously been shown in cancer research, and underscores the possibility that certain psychological responses to genetic testing may not be fully captured by commonly used scales 14. Because the CES-D and BAI are general measures of depression and anxiety, and because the IES was created as a measure of subject distress for any event, these instruments may not be appropriate for detecting psychological distress in a genetic testing situation 15-17. And even though the IES has more recently been applied to assessing the psychological impact of predictive genetic testing (e.g., Huntington’s disease, and hereditary breast and ovarian cancer), AD may be sufficiently different from other health conditions to warrant a disease specific approach to measuring the psychological impact of genetic testing 18, 19.
A couple of scales have been developed to assess the impact of genetic testing. One is The Multidimensional Impact of Cancer Risk Assessment (MICRA) Questionnaire 14. It was published in 2002 as a questionnaire used to assess the impact of cancer genetic testing with BRCA 1/2 testing as a model. It is a scale that takes into account special features of genetic testing such as the impact of the results on family members and relatives. Another available instrument is the PAGIS, or the Psychological Adaptation to Genetic Information Scale, published in 2005 20. The PAGIS is based on the conceptual framework of Skirton’s grounded theory of the client’s perspective of genetic counseling as well as on the Roy Adaptation Model 20. The goal of the scale was to isolate the impact of genetic testing regardless of the likelihood of the gene causing the disease. The PAGIS was not developed with a specific disease in mind and it appears that to date, there are no published reports using the PAGIS.
Still, the scales described above are not disease specific to AD. Thus, the purpose of the present study was to develop a brief, self-report measure of the psychological impact of genetic susceptibility tests for AD to be used in both clinical (e.g. genetic counseling) settings as well as in research on genetic risk disclosure.
Overview of REVEAL II
Because this paper will focus on the development of a new scale using data from the second REVEAL trial (REVEAL II), a brief description of the REVEAL II protocol will be given here. Additional descriptions of the clinical trial rationale, design, and results have been published elsewhere 21.
The primary aim of REVEAL II was to determine whether genetic risk assessment with APOE disclosure could be safely carried out using a condensed, clinically feasible protocol. Study participants were either randomized into the control arm, which featured a comprehensive extended protocol with multiple preparatory visits with genetic counselors, or the intervention arm, which used a shorter condensed protocol utilizing an education brochure and supplementary brief genetic counseling sessions. Participants in both arms of the study were given risk assessments based on their APOE genotype, age, gender, race, and family history. The impact of learning this information was tracked for one year with follow-up visits at six weeks, six months, and twelve months after the disclosure.
Development of the protocol was overseen and approved by a study External Advisory Board, as well as institutional review boards at each study site.
Participants
All participants were adult children of a person with clinically diagnosed and/or autopsy-confirmed AD. Of the 437 participants who enrolled in the study, a vast majority were self-referred. For example, 239 or 55% of the participants volunteered because they heard about the study from a friend, an advertisement brochure, a presentation given by a member of the REVEAL study, or another research study at any one of the four study sites. An additional 161 or 37% of the participants heard about the study through the internet, community newsletters, health fairs, other neurologists, or the Alzheimer’s Association.
Potential participants were initially screened for clinically significant levels of depression and anxiety at baseline; participants scoring above clinical thresholds on the measures of depression and anxiety (see below) were excluded from the study (n = 6) and thus never completed the newly developed instrument at follow-up. All participants who were screened out because of elevated depression and anxiety were provided with appropriate referral information for mental health consultation. Following this screening, there were 280 participants in the study who received their genetic risk assessment. Of those, 277 responded to the 6 week follow-up questionnaire, and 256 answered the questions necessary for the analysis. The respondents were of a mean age of 58.0 (S.D.=10.5) with an average of 16.1 (S.D.=2.5) years of education. 71.1% of the respondents were female, 81.25% were white, and 42.2% received a ε4+ genotype disclosure. There were no statistical differences with regard to demographic characteristics between the respondents and non-respondents. Of those participants who completed the follow-up, two were found to have elevated scores on the measures of depression and anxiety and were provided with referral information for mental health consultation.
Preliminary Item Pool
The preliminary item pool for the new instrument consisted of items from a modification of the original MICRA developed by Cella and colleagues 14. The MICRA was developed based on their belief that there were “meaningful-but as of yet unmeasured-personal and family problems and concerns related to the information transmitted during the [cancer] genetic testing experience.”(p.565) In other words, they were taking note of the anecdotal evidence on the effects of cancer genetic testing that were not measured by currently available psychiatric measurements. The same concern was true in measuring the impact of AD susceptibility genetic testing. A more sensitive test could capture the situational effects of AD genetic testing as opposed to the more generalized effects captured by other outcome measures such as BAI or CES-D. Since MICRA was one of the only validated scales designed specifically to assess the psychological impact of genetic susceptibility testing for an adult-onset disease, it provided a good basis from which to develop an AD specific scale. Furthermore, the MICRA is unique in that it is also measuring the positives effects stemming from genetic testing. That is, in addition to items that reflect the degree of anxiety, uncertainty, or regret experienced by the disclosee, which is common among many scales, the MICRA has four items that measure degrees of relief, happiness, and satisfaction experienced by the disclosee.
The original MICRA questionnaire contains three sections, but only one of the sections (Section 1) is for all respondents. Section 1 contains three subscales, a Positive subscale (4 items), a Distress subscale (6 items), and an Uncertainty subscale (9 items), and two additional items that did not fit into any of the subscales but that were retained for the Total scale (21 items). Section 2 (2 items) pertained only to those respondents who have children, and Section 3 (2 items) is for those respondents who have had or currently have cancer. The questionnaire asked the respondents to indicate whether they have experienced each statement on a four point scale (0, 1, 3, 5) in the past week. A response of 0 indicated never experiencing the statement while a 5 indicated often experiencing the statement. A higher score on any of the subscales or the total scale indicated greater psychological distress. The positive subscale is reverse scored to reflect this.
Our modification of the MICRA differed from the original questionnaire in two ways. First, sections 2 and 3 were eliminated. Section 2 was eliminated in order to have a uniform scale applicable to all respondents. Section 3 was eliminated because it is not relevant to asymptomatic individuals. Second, because the original questionnaire applied to genetic testing of cancer, the language for REVEAL’s modified scale was adapted to reflect characteristics of AD. For example, item 9 of section 1 states, “Worrying about my risk of getting cancer [or getting cancer again if you have ever been diagnosed with cancer],” was modified to read “Worrying about my risk of getting AD.” In addition to replacing “cancer” with “AD,” the clause in the parenthesis was stricken. Unlike cancer, where there are treatment options such as chemotherapy, and surgery, AD currently does not have any disease modifying therapies, and people affected by the disease do not recover. A total of 6 items, items 9-14 of section 1 from the original scale were modified in this manner.
In this form, the Modified MICRA was administered at each of the three follow-up visits. The items were accompanied by the following instructions: “The questions below are about some specific responses you may have had after receiving your genetic test results. Please answer every question….. Indicate whether you have experienced each statement never, rarely, sometimes or often in the past week, by circling the corresponding number.”
Statistical Analysis
The first goal of the statistical analyses was to reduce the initial item pool to its most parsimonious form, and to create the most psychometrically sound instrument. To accomplish this, we used Factor Analysis (FA) and calculated Cronbach’s Alpha (CA) in an alternating and iterative process to help us arrive at the final structure of the new scale. After each analysis, whether it was FA or CA, we looked for items that did not fit a set of criteria that we derived a priori, and eliminated them from the item pool. This process was continued until all of the items fit our inclusion criteria (see below), resulting in the final structure of our measure.
The FA, achieved by way of Principal Component Analysis (PCA) with Varimax rotation, was used as a test of the internal construct validity of the scale. PCA determines the number of components, or subscales, contained in the item pool, based on intercorrelations among the items. Essentially the analysis tries to explain the variance in the data by a set of latent factors by which items can be grouped. To determine the number of factors from the analysis, we examined the Scree plot and the eigenvalues. The eigenvalue is equivalent to the amount of variance in the item pool explained by each factor, and the Scree plot is simply the visual plot of the eigenvalues by the number of factors. Our a priori criteria for determining the number of components to retain included a combination of eigenvalues greater than 1, and breaks in the curve of the Scree plot 22.
To determine which items would constitute each factor, we looked at factor loading values. Prior to initiating our analysis, we set the inclusion criteria for each factor at 0.50, and the exclusion criteria at 0.20. Thus, for an item to be retained and included in a factor, it needed to have a factor loading value of greater than 0.50 for one factor, and factor loading values of less than 0.20 for all other factors. If an item had a factor loading value of greater than 0.20 for more than one factor, or if an item did not have a factor loading value of greater than 0.50, then the item was eliminated.
CA was used to measure the resulting factors’ internal consistency, or the extent to which the items within each of the factors measured the same domain or construct. The measure is essentially an average correlation of the items within the test or subtest 23. Additional analyses using CA evaluated the correlation of each item with the rest of the factor item pool. After an item in the pool is removed, the alpha was calculated for the remaining items. After the alpha was calculated, the removed item is placed back in the pool and the next item is removed for the next alpha calculation. This procedure is repeated for every item in the pool. If the alpha value increases after an item is removed, then the conclusion can be drawn that the removed item is not highly correlated with the rest of the items. Similarly, if the alpha value decreases after an item is removed, then it can be concluded that the removed item is highly correlated with the rest of the pool. Using this method, we were able to eliminate items that were not highly correlated with the rest of the factor item pool (i.e., those items whose removal increased the alphas value).
After two iterations of FA and CA, we were left with only items that fit the inclusion criteria described above, leaving the final structure which we have named the REVEAL Impact of Genetic Testing in Alzheimer’s Disease (IGT-AD) Scale. Next, we used Spearman’s correlations to compare this final form of the IGT-AD with other more established psychometric scales (see below) as a measure of construct validity.
Other Measures
The Impact of Event Scale (IES) is a 15-item self-report measure that assesses 2 common responses related to a specific stressful life event: intrusion and avoidance 17, 24. It is a reliable scale that can be anchored to any specific life event and permits the assessment of participants over time, comparison of the degree of distress among subgroups, and comparison of the impact of various events 25. The IES has been specifically anchored to test-related distress in previous genetic testing studies 15, 26. For the purpose of this study, the total IES (range: 0 – 75) was used.
The Center for Epidemiologic Studies Depression Scale (CES-D) 16, 27-29 was originally developed as a measure of depressive symptoms in community-dwelling adults and has been widely used as a screening instrument in studies of non-clinical populations. The 20 items are rated on a 4 point scale according to the frequency with which symptoms were experienced during the preceding week and are summed to compute a total score (range: 0 – 60). The CES-D shows good internal consistency for the general population 28 and correlates strongly with the Beck Depression Inventory 29.
The Beck Anxiety Inventory (BAI) 30 is a 21-item screening test designed to distinguish common symptoms of anxiety from those of depression and to be sensitive to treatment change. It has been extensively validated and has shown excellent test-retest reliability and internal validity 31. The BAI is scored on the basis of self-reported severity of a given symptom over the past week for 0 (not at all) to 3 (severely), yielding a total score from 0 to 63.
Two iterations of FA and CA were performed to eliminate items that did not fit the inclusion criteria. The first iteration reduced the number of items from twenty-one to seventeen, and the second iteration eliminated one more item reducing the total number of items to sixteen (Table 1).
Table 1
Table 1
Items Deleted from the Preliminary Item Pool
Of the four items that were eliminated from the original item pool during the first iteration, three items (4, 12, 15) were excluded because they did not satisfy the inclusion criteria of the FA, and one item (13) was excluded because it did not satisfy the inclusion criteria of the CA. During the second iteration, item 20 was eliminated following FA because it did not have a factor loading value of greater than 0.50 for either of the two factors.
Based on the eigenvalue criteria of greater than one, six factors could potentially be identified in the scale. However, examination of the Scree plot, which identified the possibility of two or three factors, and the factor loading coefficients, revealed that two factors were optimal. Factor one, which we named the distress subscale due to the context of the items, explained 32.9% of the total variance, and factor two, which we named the positive subscale, explained 16.7% of the total variance. Thus, the two components together explain 49.6% of the total variance (Table 2) which is typically considered acceptable for this type of scale development. Although the original MICRA contained three components, our analyses suggest that two of the original components (the distress subscale and the uncertainty subscale) are not measuring significantly different dimensions of psychological impact as it pertains to AD genetic testing.
Table 2
Table 2
Varimax Rotated Component Pattern of the Final 16 REVEAL IGT-AD Items
The CA analysis eliminated any items that led to a significantly lower alpha value when deleted. The raw alpha was used for comparison when evaluating internal reliability of each component separately, but the standardized alpha was used when evaluating both components together since the two components have dissimilar variances. The distress subscale, which contains 12 items, has an alpha value of 0.86, and the positive subscale, which contains 4 items, has an alpha value of 0.82. The total scale also has an alpha value of 0.82.
Table 3 presents the final REVEAL IGT-AD Scale items. The individual items of each subscale are summed to form a score for each subscale. The items of the positive subscale are reversed before summation (i.e. a “5” becomes a “0,” a “3” becomes a “1,” and vice versa). The score of the total scale is the sum of the two subscale scores. Descriptive statistics of IGT-AD and other scales are presented in Table 4.
Table 3
Table 3
REVEAL IGT-AD total scale and its components.
Table 4
Table 4
REVEAL IGT-AD and Other Scale Descriptive Statistics
To establish the scale’s external validity, the IGT-AD was compared to other more established scales, using Spearman rank order correlations (Table 5). IGT-AD Total and the distress subscale are positively correlated with IES, BAI and CES-D indicating convergent validity. Furthermore, the positive subscale is negatively correlated with IES, and BAI, and it is essentially uncorrelated with CES-D, indicating divergent validity.
Table 5
Table 5
Construct Validity: Spearman Correlations with Other Scales.
The IGT-AD is the first and only scale developed to assess the psychological impact of AD genetic susceptibility testing. Results of this study indicate that it is a valid, reliable scale that may be more appropriate for measuring the impact of genetic susceptibility testing in AD than generalized mood scales or other event specific scales not sensitive to issues unique to genetic testing. This scale addresses the unique nature of genetic information as it relates to AD and isolates the impact of this genetic information. The IGT-AD has a number of unique features. For example, its item content is specific to issues pertaining to AD genetic testing. Second, the inclusion of a distress subscale and positive subscale allows for the measurement of both constructs in the same overall scale. For example, in the context of APOE genetic testing, a respondent can be distressed about being homozygous for the ε4 allele, but at the same time be relieved that his or her risk of getting AD is not as high as he or she thought. Having a positive and a negative component allows the IGT-AD to parse out two distinct potential reactions.
Limitations
One limitation of the IGT-AD is that it was not initially developed with direct input from expert clinicians (e.g., neurologists, psychiatrists, and psychologists), genetic counselors, geneticists or likely respondents to the questionnaire. The scale was adapted from the MICRA 14, which was developed specifically for cancer genetic testing, using participants interested in breast cancer genetic information. Thus, due to differences in the age of onset, affected population, risk estimates, and treatment options between AD and breast cancer, the IGT-AD may lack some sensitivity to AD genetic susceptibility testing. In addition, because six potential participants were screened out prior to the study, due to elevated CES-D and BAI scores, and because the CES-D and BAI were both found to be correlated with the IGT at follow-up, it is possible that our sample may have had an artificially suppressed range of scores on the IGT-AD. Despite these limitations, the preliminary statistical analyses presented here suggest that the new scale has excellent internal reliability and construct validity, and that it is in fact measuring additional element(s) not captured by the other established scales. Further assessment of the validity of the new IGT-AD with additional convergent and divergent measures would be helpful.
Another limitation of the study is the generalizability of the scale to the population at large. So far, the psychometric properties of the scale have only been tested on a single research population. REVEAL II participants reflect, for the most part, a particular segment of the society (i.e. female, white, educated, and belonging to a higher socioeconomic class), though it should be noted that African Americans were actively recruited as a part of the study protocol and make up a substantial percentage of the study participants, especially when compared to other clinical trials. Thus, both the validity and the reliability of the IGT-AD need to be evaluated further in other populations that are more heterogeneous in their ethnic, gender, and socioeconomic makeup. Finally, it should be noted that results of this group-based study may not be appropriate for interpretation at the individual level. That is, further clinically-based studies would be warranted before utilizing the IGT-AD for individual clinical interpretation.
Conclusion
The REVEAL IGT-AD is a valid and reliable scale that can be used to measure the impact of genetic testing for AD (see appendix for the complete REVEAL IGT-AD scale). As research on genetic testing for AD becomes more prominent, driven by the increased prevalence of AD, consumer knowledge of genetics, and scientific knowledge of the genetic components of AD, a scale like the IGT-AD can aid in understanding the impact of genetic testing of AD. Used as an outcome measure, factors which lead to less desirable outcomes due to AD genetic testing (i.e. sadness, anger, and/or guilt) can be identified. As genetic testing of AD becomes more common, these studies would help identify those patients who may be at risk for associated distress and who may benefit from additional intervention.
Acknowledgements
This research was supported by NIH grants RO1-HG/AG-02213 (The REVEAL Study), K24-AG027841, RO1-AG09029 (The MIRAGE Study), P30-AG13846 (Boston University Alzheimer’s Disease Core Center), M01-RR00533 (Boston University General Clinical Research Center).
Appendix
The REVEAL Impact of Genetic Testing in Alzheimer’s Disease (IGT-AD) ScaleThe questions below are about specific responses you may have had after receiving your genetic test results. Please answer every question in this section. Indicate whether you have experienced each statement never, rarely, sometimes or often in the past week, by circling the corresponding number.
In the past week, I have experienced…NeverRarelySometimesOften
1. Feeling upset about my test result0135
2. Feeling sad about my test result0135
3. Feeling anxious or nervous about my test result0135
4. Feeling relieved about my test result0135
5. Feeling happy about my test result0135
6. Feeling a loss of control0135
7. Having problems enjoying life because of my test
 result
0135
8. Worrying about my risk of getting Alzheimer’s
 disease
0135
9. Being uncertain about what my test result means
 about my risk of developing Alzheimer’s disease.
0135
10. Being uncertain about what my test result means for
 my child(ren)’s and/or family’s Alzheimer’s disease
risk.
0135
11. Feeling frustrated that there are no definite
 Alzheimer’s disease prevention guidelines for me.
0135
12. Feeling concerned about how my test results will
 affect my insurance status
0135
13. Having difficulty talking about my test results with
 family members
0135
14. Feeling that my family has been supportive during
 genetic counseling and testing process
0135
15. Feeling satisfied with family communication about
 my genetic test result
0135
16. Feeling regret about getting my test results0135
Notes: Distress Subscale contains items 1-3, 6-13, and 16. Positive Subscale contains items 4, 5, 14, and 15. Total Scale and subscales are scored by summing circled numbers. The Positive Subscale is reverse scored.
1. Green RC. Diagnosis and Management of Alzheimer’s Disease and Other Dementias. Second Professional Communications, Inc.; 2005.
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–22. [PubMed]
3. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health. 2002;23:213–31. [PubMed]
4. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278(16):1349–56. [PubMed]
5. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168–77. [PMC free article] [PubMed]
6. Brodaty H, Conneally M, Gauthier S, et al. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9(4):182–7. [PubMed]
7. Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein E testing for Alzheimer’s disease. JAMA. 1995;274:1627–1629. [PubMed]
8. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. Jama. 1997;277(10):832–6. [PubMed]
9. Relkin NR, Kwon YJ, Tsai J, et al. The National Institute on Aging/Alzheimer’s Association recommendations on the application of apolipoprotein E genotyping to Alzheimer’s disease. Ann N Y Acad Sci. 1996;802:149–76. [PubMed]
10. Brown T, Roberts JS, LaRusse S, et al. Impact of genetic risk assessment for Alzheimer’s disease. J Genet Couns. 2002;11:446–447.
11. Roberts JS, Green RC, Relkin NR, et al. How do participants rate the impact of genetic susceptibility testing for Alzheimer’s disease? Neurology. 2003;60:A453.
12. Roberts JS, Lock M, Prest J, et al. How does genetic testing affect anxiety about developing AD? Neurobiol Aging. 2004;25(suppl2):509. [PubMed]
13. Gooding HC, Linnenbringer EL, Burack J, et al. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns. 2006;64(13):259–67. [PubMed]
14. Cella D, Hughes C, Peterman A, et al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002;21(6):564–72. [PubMed]
15. Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. J Anxiety Disord. 2006;20(4):444–58. [PubMed]
16. Radloff L. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement. 1977;1(3):385–401.
17. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–18. [PubMed]
18. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet. 2000;8(10):731–8. [PubMed]
19. Sundin EC, Horowitz MJ. Impact of Event Scale: psychometric properties. Br J Psychiatry. 2002;180:205–9. [PubMed]
20. Read CY, Perry DJ, Duffy ME. Design and psychometric evaluation of the Psychological Adaptation to Genetic Information Scale. J Nurs Scholarsh. 2005;37(3):203–8. [PubMed]
21. Green RC, Roberts JS, Chen C, et al. Comparing the impact of a condensed vs extended protocol for disclosure of APOE to relatives of patients with AD: The REVEAL Study. Alzheimer’s and Dementia. 2007;3:S184.
22. Cattell RB. The Scree test for the number of factors. Multivariate Behavioral Research. 1966;1:245–276.
23. Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;16(2):167–88. [PubMed]
24. Zilberg NJ, Weiss DS, Horowitz MJ. Impact of Event Scale: A cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. Journal of Consulting and Clinical Psychology. 1982;50:407–414. [PubMed]
25. Tennen H, Herzberger S. Impact of Events Scale. In: Sweetland RC, Keyser DJ, editors. Test Critiques. Test Corporation of America; Kansas City, MO: 1985. pp. 358–366.
26. Reichelt JG, Dahl AA, Heimdal K, et al. Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations. Dis Markers. 1999;15:139–143. [PubMed]
27. Vernon SW, Gritz ER, Peterson SK, et al. Correlates of psychologic distress in colorectal cancer patients undergoing genetic testing for hereditary colon cancer. Health Psychology. 1997;16(1):73–86. [PubMed]
28. Corcoran K, Fisher J. Measures for Clinical Practice: A Source Book. Free Press; New York: 1987.
29. Santor DA, Zuroff DC, Ramsay JO, et al. Examining scale discriminability in the BDI and CES-D as a function of depressive sererity. Psychological Assessment. 1995;7:131–139.
30. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7. [PubMed]
31. Wetherell JL, Arean PA. Psychometric evaluation of the Beck Anxiety Inventory with older medical patients. Psychological Assessment. 1997;9(2):136–144.